NASDAQ:CYRX - Nasdaq - US2290503075 - Common Stock - Currency: USD
CYRX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 56 industry peers in the Life Sciences Tools & Services industry. While CYRX seems to be doing ok healthwise, there are quite some concerns on its profitability. CYRX is valied quite expensively at the moment, while it does show a decent growth rate.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -17.45% | ||
ROE | -30.54% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 43.62% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.46 | ||
Debt/FCF | N/A | ||
Altman-Z | -0.48 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 5.29 | ||
Quick Ratio | 4.94 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
5.46
-0.12 (-2.15%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 1.19 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 0.68 | ||
P/tB | 1.52 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -17.45% | ||
ROE | -30.54% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 43.62% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.46 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 69.15% | ||
Cap/Sales | 9.31% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 5.29 | ||
Quick Ratio | 4.94 | ||
Altman-Z | -0.48 |